

References

References

1. 't Hart,B.A. & Amor,S. The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system. *Curr. Opin. Neurol.* **16**, 375-383 (2003).
2. 't Hart,B.A. *et al.* Modelling of multiple sclerosis: lessons learned in a non-human primate. *Lancet Neurol.* **3**, 588-597 (2004).
3. Abbott,N.J., Revest,P.A., & Romero,J.A. Astrocyte-endothelial interaction: physiology and pathology. *Neuropathol. Appl. Neurobiol.* **18**, 424-433 (1992).
4. Abbott,N.J., Ronnback,L., & Hansson,E. Astrocyte-endothelial interactions at the blood-brain barrier. *Nat. Rev. Neurosci.* **7**, 41-53 (2006).
5. Achyuthan,K.E. *et al.* Immunochemical analyses of human plasma fibronectin-cytosolic transglutaminase interactions. *J. Immunol. Methods* **180**, 69-79 (1995).
6. Achyuthan,K.E. & Greenberg,C.S. Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. *J. Biol. Chem.* **262**, 1901-1906 (1987).
7. Aeschlimann,D. & Thomazy,V. Protein crosslinking in assembly and remodeling of extracellular matrices: the role of transglutaminases. *Connect. Tissue Res.* **41**, 1-27 (2000).
8. Ahn,J.S. *et al.* Tissue transglutaminase-induced down-regulation of matrix metalloproteinase-9. *Biochem. Biophys. Res. Commun.* **376**, 743-747 (2008).
9. Akimov,S.S. & Belkin,A.M. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. *Blood* **98**, 1567-1576 (2001).
10. Akimov,S.S., Krylov,D., Fleischman,L.F., & Belkin,A.M. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. *J. Cell Biol.* **148**, 825-838 (2000).
11. Al-Omaishi,J., Bashir,R., & Gendelman,H.E. The cellular immunology of multiple sclerosis. *J. Leukoc. Biol.* **65**, 444-452 (1999).
12. Aloisi,F. Immune function of microglia. *Glia* **36**, 165-179 (2001).
13. Amano,M., Fukata,Y., & Kaibuchi,K. Regulation and functions of Rho-associated kinase. *Exp. Cell Res.* **261**, 44-51 (2000).
14. Ambrus,A. *et al.* Calcium binding of transglutaminases: a ⁴³Ca NMR study combined with surface polarity analysis. *J. Biomol. Struct. Dyn.* **19**, 59-74 (2001).
15. Amendola,A. *et al.* Induction of "tissue" transglutaminase in HIV pathogenesis: evidence for high rate of apoptosis of CD4+ T lymphocytes and accessory cells in lymphoid tissues. *Proc. Natl. Acad. Sci. U. S. A* **93**, 11057-11062 (1996).
16. Andringa,G. *et al.* Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. *FASEB J.* **18**, 932-934 (2004).
17. Antonyak,M.A. *et al.* Two isoforms of tissue transglutaminase mediate opposing cellular fates. *Proc. Natl. Acad. Sci. U. S. A* **103**, 18609-18614 (2006).
18. Antonyak,M.A. *et al.* Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis. *J. Biol. Chem.* **276**, 33582-33587 (2001).
19. Bailey,C.D., Graham,R.M., Nanda,N., Davies,P.J., & Johnson,G.V. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases. *Mol. Cell Neurosci.* **25**, 493-503 (2004).
20. Balajthy,Z. *et al.* Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions. *Blood* **108**, 2045-2054 (2006).
21. Baldwin,S.A. & Scheff,S.W. Intermediate filament change in astrocytes following mild cortical contusion. *Glia* **16**, 266-275 (1996).
22. Balklava,Z. *et al.* Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. *J. Biol. Chem.* **277**, 16567-16575 (2002).
23. Bannerman,P., Hahn,A., Soulika,A., Gallo,V., & Pleasure,D. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. *Glia* **55**, 57-64 (2007).
24. Barkhof,F. *et al.* Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. *Arch. Neurol.* **60**, 1073-1081 (2003).
25. Barone,M.V. *et al.* Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease. *Gastroenterology* **132**, 1245-1253 (2007).
26. Bauer,J. *et al.* Astrocytes are a specific immunological target in Rasmussen's encephalitis. *Ann. Neurol.* **62**, 67-80 (2007).
27. Baumann,N. & Pham-Dinh,D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. *Physiol Rev.* **81**, 871-927 (2001).
28. Beamer,N.B. *et al.* Persistent inflammatory response in stroke survivors. *Neurology* **50**, 1722-1728 (1998).
29. Becher,B., Prat,A., & Antel,J.P. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. *Glia* **29**, 293-304 (2000).
30. Begg,G.E. *et al.* Mechanism of allosteric regulation of transglutaminase 2 by GTP. *Proc. Natl. Acad. Sci. U. S. A* **103**, 19683-19688 (2006).
31. Beninati,S. & Piacentini,M. The transglutaminase family: an overview: minireview article. *Amino. Acids* **26**, 367-372 (2004).
32. Benveniste,E.N. Cytokine actions in the central nervous system. *Cytokine Growth Factor Rev.* **9**, 259-275 (1998).
33. Bergamini,C.M. *et al.* Thermodynamics of binding of regulatory ligands to tissue transglutaminase. *Amino. Acids* (2009).

34. Bergamini,C.M., Griffin,M., & Pansini,F.S. Transglutaminase and vascular biology: physiopathologic implications and perspectives for therapeutic interventions. *Curr. Med. Chem.* **12**, 2357-2372 (2005).
35. Bernassola,F. *et al.* Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient. *FASEB J.* **16**, 1371-1378 (2002).
36. Berry,M. *et al.* Deposition of scar tissue in the central nervous system. *Acta Neurochir. Suppl (Wien.)* **32**, 31-53 (1983).
37. Birckbichler,P.J., Orr,G.R., Patterson,M.K., Jr., Conway,E., & Carter,H.A. Increase in proliferative markers after inhibition of transglutaminase. *Proc. Natl. Acad. Sci. U. S. A* **78**, 5005-5008 (1981).
38. Bishop,A.L. & Hall,A. Rho GTPases and their effector proteins. *Biochem. J.* **348 Pt 2**, 241-255 (2000).
39. Blakemore,W.F. Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. *J. Neurocytol.* **1**, 413-426 (1972).
40. Blanchette,F. & Neuhaus,O. Glatiramer acetate: evidence for a dual mechanism of action. *J. Neurol.* **255 Suppl 1**, 26-36 (2008).
41. Bo,L. *et al.* Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. *Ann. Neurol.* **36**, 778-786 (1994).
42. Bo,L., Geurts,J.J., Ravid,R., & Barkhof,F. Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis. *Neuropathol. Appl. Neurobiol.* **30**, 106-117 (2004).
43. Bo,L. *et al.* Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. *J. Neuroimmunol.* **51**, 135-146 (1994).
44. Bonelli,R.M., Aschoff,A., Niederwieser,G., Heuberger,C., & Jirikowski,G. Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease. *Neurobiol. Dis.* **11**, 106-110 (2002).
45. Bouzier-Sore,A.K., Merle,M., Magistretti,P.J., & Pellerin,L. Feeding active neurons: (re)emergence of a nursing role for astrocytes. *J. Physiol Paris* **96**, 273-282 (2002).
46. Boven,L.A., Middel,J., Verhoef,J., De Groot,C.J., & Nottet,H.S. Monocyte infiltration is highly associated with loss of the tight junction protein zonula occludens in HIV-1-associated dementia. *Neuropathol. Appl. Neurobiol.* **26**, 356-360 (2000).
47. Breve,J.J., Drukarch,B., van Strien,M., & van Dam,A.M. Validated sandwich ELISA for the quantification of tissue transglutaminase in tissue homogenates and cell lysates of multiple species. *J. Immunol. Methods* **332**, 142-150 (2008).
48. Brosnan,C.F., Cannella,B., Battistini,L., & Raine,C.S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. *Neurology* **45**, S16-S21 (1995).
49. Bruck,W., Kuhlmann,T., & Stadelmann,C. Remyelination in multiple sclerosis. *J. Neurol. Sci.* **206**, 181-185 (2003).
50. Bruck,W. *et al.* Macrophages in multiple sclerosis. *Immunobiology* **195**, 588-600 (1996).
51. Buchli,A.D. & Schwab,M.E. Inhibition of Nogo: a key strategy to increase regeneration, plasticity and functional recovery of the lesioned central nervous system. *Ann. Med.* **37**, 556-567 (2005).
52. Butt,A.M. & Dinsdale,J. Fibroblast growth factor 2 mediated disruption of myelin-forming oligodendrocytes in vivo is associated with increased tau immunoreactivity. *Neurosci. Lett.* **375**, 28-32 (2005).
53. Butt,A.M., Duncan,A., & Berry,M. Astrocyte associations with nodes of Ranvier: ultrastructural analysis of HRP-filled astrocytes in the mouse optic nerve. *J. Neurocytol.* **23**, 486-499 (1994).
54. Buttery,P.C. & Ffrench-Constant,C. Laminin-2/integrin interactions enhance myelin membrane formation by oligodendrocytes. *Mol. Cell Neurosci.* **14**, 199-212 (1999).
55. Campisi,A. *et al.* Glutamate-induced increases in transglutaminase activity in primary cultures of astroglial cells. *Brain Res.* **978**, 24-30 (2003).
56. Campisi,A. *et al.* Transglutaminase activity in primary and subcultured rat astroglial cells. *Neurochem. Res.* **17**, 1201-1205 (1992).
57. Candi,E. *et al.* Transglutaminase 5 cross-links loricrin, involucrin, and small proline-rich proteins in vitro. *J. Biol. Chem.* **276**, 35014-35023 (2001).
58. Cao,L. *et al.* Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. *Carcinogenesis* **29**, 1893-1900 (2008).
59. Carlton,W.W. Response of mice to the chelating agents sodium diethyldithiocarbamate, alpha-benzoinoxime, and bis(cyclohexanone oxaldihydrazone). *Toxicol. Appl. Pharmacol.* **8**, 512-521 (1966).
60. Carlton,W.W. Studies on the induction of hydrocephalus and spongy degeneration by cuprizone feeding and attempts to antidote the toxicity. *Life Sci.* **6**, 11-19 (1967).
61. Carson,M.J., Doose,J.M., Melchior,B., Schmid,C.D., & Ploix,C.C. CNS immune privilege: hiding in plain sight. *Immunol. Rev.* **213**, 48-65 (2006).
62. Carvalho-Tavares,J. *et al.* A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. *Circ. Res.* **87**, 1141-1148 (2000).
63. Casadio,R. *et al.* The structural basis for the regulation of tissue transglutaminase by calcium ions. *Eur. J. Biochem.* **262**, 672-679 (1999).
64. Chang,A., Nishiyama,A., Peterson,J., Prineas,J., & Trapp,B.D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. *J. Neurosci.* **20**, 6404-6412 (2000).
65. Chavarria,A. & cocer-Varela,J. Is damage in central nervous system due to inflammation? *Autoimmun. Rev.* **3**, 251-260 (2004).
66. Chen,J.S. & Mehta,K. Tissue transglutaminase: an enzyme with a split personality. *Int. J. Biochem. Cell Biol.*

- 31**, 817-836 (1999).
67. Chhabra,A., Verma,A., & Mehta,K. Tissue transglutaminase promotes or suppresses tumors depending on cell context. *Anticancer Res.* **29**, 1909-1919 (2009).
 68. Choi,K. *et al.* Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. *Chem. Biol.* **12**, 469-475 (2005).
 69. Chung,A.S., Gao,Q., & Kao,W.J. Either integrin subunit beta1 or beta3 is involved in mediating monocyte adhesion, IL-1beta protein and mRNA expression in response to surfaces functionalized with fibronectin-derived peptides. *J. Biomater. Sci. Polym. Ed* **18**, 713-729 (2007).
 70. Citron,B.A. *et al.* Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. *Neurochem. Int.* **40**, 69-78 (2002).
 71. Citron,B.A., Zoloty,J.E., Suo,Z., & Festoff,B.W. Tissue transglutaminase during mouse central nervous system development: lack of alternative RNA processing and implications for its role(s) in murine models of neurotrauma and neurodegeneration. *Brain Res. Mol. Brain Res.* **135**, 122-133 (2005).
 72. Clarce,D.D., Neidle,A., Sarkar,N.K., & Waelsch,H. Metabolic activity of protein amide groups. *Arch. Biochem. Biophys.* **71**, 277-279 (1957).
 73. Collighan,R.J. & Griffin,M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. *Amino. Acids* **36**, 659-670 (2009).
 74. Colton,C.A. & Wilcock,D.M. Assessing activation states in microglia. *CNS. Neurol. Disord. Drug Targets.* **9**, 174-191 (2010).
 75. Compston,A. & Coles,A. Multiple sclerosis. *Lancet* **359**, 1221-1231 (2002).
 76. Confavreux,C., Vukusic,S., Moreau,T., & Adeleine,P. Relapses and progression of disability in multiple sclerosis. *N. Engl. J. Med.* **343**, 1430-1438 (2000).
 77. Couraud,P.O. Infiltration of inflammatory cells through brain endothelium. *Pathol. Biol. (Paris)* **46**, 176-180 (1998).
 78. Curtis,C.G. & Lorand,L. Fibrin-stabilizing factor (factor XIII). *Methods Enzymol.* **45**, 177-191 (1976).
 79. Czopka,T., Von,H.A., Schmidt,G., Ffrench-Constant,C., & Faissner,A. Tenascin C and tenascin R similarly prevent the formation of myelin membranes in a RhoA-dependent manner, but antagonistically regulate the expression of myelin basic protein via a separate pathway. *Glia* **57**, 1790-1801 (2009).
 80. Datta,S., Antonyak,M.A., & Cerione,R.A. Importance of Ca(2+)-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis. *Biochemistry* **45**, 13163-13174 (2006).
 81. De Bleecker,J.L., Leroy,B.P., & Meire,V.I. Reversible visual deficit and Corpus callosum lesions due to metronidazole toxicity. *Eur. Neurol.* **53**, 93-95 (2005).
 82. De Groot,C.J. *et al.* Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. *Brain* **124**, 1635-1645 (2001).
 83. De Vos,A.F. *et al.* Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. *J. Immunol.* **169**, 5415-5423 (2002).
 84. De Vries,H.E. *et al.* Signal-regulatory protein alpha-CD47 interactions are required for the transmigration of monocytes across cerebral endothelium. *J. Immunol.* **168**, 5832-5839 (2002).
 85. De Laurenzi,V., & Melino,G. Gene disruption of tissue transglutaminase. *Mol. Cell Biol.* **21**, 148-155 (2001).
 86. Dedeoglu,A. *et al.* Therapeutic effects of cystamine in a murine model of Huntington's disease. *J. Neurosci.* **22**, 8942-8950 (2002).
 87. Des Tombe,A.L., Van Beek-Harmsen,B.J., Lee-De Groot,M.B., & van der Laarse,W.J. Calibrated histochemistry applied to oxygen supply and demand in hypertrophied rat myocardium. *Microsc. Res. Tech.* **58**, 412-420 (2002).
 88. DeSilva,B. *et al.* Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. *Pharm. Res.* **20**, 1885-1900 (2003).
 89. Didier,N. *et al.* Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. *J. Neurochem.* **86**, 246-254 (2003).
 90. Dieterich,W. *et al.* Identification of tissue transglutaminase as the autoantigen of celiac disease. *Nat. Med.* **3**, 797-801 (1997).
 91. Dinarello,C.A. Interleukin-1 and interleukin-1 antagonism. *Blood* **77**, 1627-1652 (1991).
 92. Dinarello,C.A. & Thompson,R.C. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. *Immunol. Today* **12**, 404-410 (1991).
 93. Dubois-Dalco,M., Ffrench-Constant,C., & Franklin,R.J. Enhancing central nervous system remyelination in multiple sclerosis. *Neuron* **48**, 9-12 (2005).
 94. Duncan,I.D., Brower,A., Kondo,Y., Curlee,J.F., Jr., & Schultz,R.D. Extensive remyelination of the CNS leads to functional recovery. *Proc. Natl. Acad. Sci. U. S. A* **106**, 6832-6836 (2009).
 95. Eddleston,M. & Mucke,L. Molecular profile of reactive astrocytes--implications for their role in neurologic disease. *Neuroscience* **54**, 15-36 (1993).
 96. Encinas,M. *et al.* Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. *J. Neurochem.* **75**, 991-1003 (2000).
 97. Eng,L.F. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. *J. Neuroimmunol.* **8**, 203-214 (1985).
 98. Engelhardt,B. & Kappos,L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. *Neurodegener. Dis.*

- 5, 16-22 (2008).
99. Erschbamer,M.K., Hofstetter,C.P., & Olson,L. RhoA, RhoB, RhoC, Rac1, Cdc42, and Tc10 mRNA levels in spinal cord, sensory ganglia, and corticospinal tract neurons and long-lasting specific changes following spinal cord injury. *J. Comp Neurol.* **484**, 224-233 (2005).
 100. Fadok,V.A., McDonald,P.P., Bratton,D.L., & Henson,P.M. Regulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells. *Biochem. Soc. Trans.* **26**, 653-656 (1998).
 101. Falasca,L. *et al.* Transglutaminase type II is involved in the pathogenesis of endotoxic shock. *J. Immunol.* **180**, 2616-2624 (2008).
 102. Farias,A.S. *et al.* Nitric oxide and TNFalpha effects in experimental autoimmune encephalomyelitis demyelination. *Neuroimmunomodulation.* **14**, 32-38 (2007).
 103. Fawcett,J.W. & Asher,R.A. The glial scar and central nervous system repair. *Brain Res. Bull.* **49**, 377-391 (1999).
 104. Felts,P.A., Baker,T.A., & Smith,K.J. Conduction in segmentally demyelinated mammalian central axons. *J. Neurosci.* **17**, 7267-7277 (1997).
 105. Fesus,L. & Arato,G. Quantitation of tissue transglutaminase by a sandwich ELISA system. *J. Immunol. Methods* **94**, 131-136 (1986).
 106. Fesus,L. & Piacentini,M. Transglutaminase 2: an enigmatic enzyme with diverse functions. *Trends Biochem. Sci.* **27**, 534-539 (2002).
 107. Fesus,L., Thomazy,V., & Falus,A. Induction and activation of tissue transglutaminase during programmed cell death. *FEBS Lett.* **224**, 104-108 (1987).
 108. Ffrench-Constant,C. & Raff,M.C. The oligodendrocyte-type-2 astrocyte cell lineage is specialized for myelination. *Nature* **323**, 335-338 (1986).
 109. Fidler,J.M., DeJoy,S.Q., & Gibbons,J.J., Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. *J. Immunol.* **137**, 727-732 (1986).
 110. Fisher,M. *et al.* Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. *Matrix Biol.* **28**, 20-31 (2009).
 111. Floris,S. *et al.* Interferon-beta directly influences monocyte infiltration into the central nervous system. *J. Neuroimmunol.* **127**, 69-79 (2002).
 112. Fok,J.Y. & Mehta,K. Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells. *Apoptosis.* **12**, 1455-1463 (2007).
 113. Folk,J.E. Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation. *Adv. Enzymol. Relat Areas Mol. Biol.* **54**, 1-56 (1983).
 114. Folk,J.E. & Chung,S.I. Transglutaminases. *Methods Enzymol.* **113**, 358-375 (1985).
 115. Folk,J.E. & Finlayson,J.S. The epsilon-(gamma-glutamyl)lysine crosslink and the catalytic role of transglutaminases. *Adv. Protein Chem.* **31**, 1-133 (1977).
 116. Forsprecher,J., Wang,Z., Nelea,V., & Kaartinen,M.T. Enhanced osteoblast adhesion on transglutaminase 2-crosslinked fibronectin. *Amino. Acids* **36**, 747-753 (2009).
 117. Franco-Pons,N., Torrente,M., Colomina,M.T., & Vilella,E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. *Toxicol. Lett.* **169**, 205-213 (2007).
 118. Franklin,R.J. Why does remyelination fail in multiple sclerosis? *Nat. Rev. Neurosci.* **3**, 705-714 (2002).
 119. Franklin,R.J. & Ffrench-Constant,C. Remyelination in the CNS: from biology to therapy. *Nat. Rev. Neurosci.* **9**, 839-855 (2008).
 120. Franklin,R.J., Hinks,G.L., Woodruff,R.H., & O'Leary,M.T. What roles do growth factors play in CNS remyelination? *Prog. Brain Res.* **132**, 185-193 (2001).
 121. Fressinaud,C., Laeng,P., Labourdette,G., Durand,J., & Vallat,J.M. The proliferation of mature oligodendrocytes in vitro is stimulated by basic fibroblast growth factor and inhibited by oligodendrocyte-type 2 astrocyte precursors. *Dev. Biol.* **158**, 317-329 (1993).
 122. Fridkis-Hareli,M. *et al.* Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. *Proc. Natl. Acad. Sci. U. S. A* **91**, 4872-4876 (1994).
 123. Frohman,E.M., Racke,M.K., & Raine,C.S. Multiple sclerosis--the plaque and its pathogenesis. *N. Engl. J. Med.* **354**, 942-955 (2006).
 124. Furlan,R., Cuomo,C., & Martino,G. Animal models of multiple sclerosis. *Methods Mol. Biol.* **549**, 157-173 (2009).
 125. Gahl,W.A., Thoene,J.G., & Schneider,J.A. Cystinosis. *N. Engl. J. Med.* **347**, 111-121 (2002).
 126. Gard,A.L., Burrell,M.R., Pfeiffer,S.E., Rudge,J.S., & Williams,W.C. Astroglial control of oligodendrocyte survival mediated by PDGF and leukemia inhibitory factor-like protein. *Development* **121**, 2187-2197 (1995).
 127. Gaudry,C.A. *et al.* Cell surface localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal beta-sandwich domain. *J. Biol. Chem.* **274**, 30707-30714 (1999).
 128. Gaudry,C.A., Verderio,E., Jones,R.A., Smith,C., & Griffin,M. Tissue transglutaminase is an important player at the surface of human endothelial cells: evidence for its externalization and its colocalization with the beta(1) integrin. *Exp. Cell Res.* **252**, 104-113 (1999).
 129. Gehrmann,J., Matsumoto,Y., & Kreutzberg,G.W. Microglia: intrinsic immune effector cell of the brain. *Brain Res. Brain Res. Rev.* **20**, 269-287 (1995).
 130. George,M.D., Vollberg,T.M., Floyd,E.E., Stein,J.P., & Jetten,A.M. Regulation of transglutaminase type II by transforming growth factor-beta 1 in normal and transformed human epidermal keratinocytes. *J.*

- Biol. Chem.* **265**, 11098-11104 (1990).
131. Ghalie,R.G. *et al.* Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. *Neurology* **59**, 909-913 (2002).
 132. Gimenez,M.A., Sim,J., Archambault,A.S., Klein,R.S., & Russell,J.H. A tumor necrosis factor receptor 1-dependent conversation between central nervous system-specific T cells and the central nervous system is required for inflammatory infiltration of the spinal cord. *Am. J. Pathol.* **168**, 1200-1209 (2006).
 133. Goldschmidt,T., Antel,J., Konig,F.B., Bruck,W., & Kuhlmann,T. Remyelination capacity of the MS brain decreases with disease chronicity. *Neurology* **72**, 1914-1921 (2009).
 134. Gonzalez-Scarano,F. & Baltuch,G. Microglia as mediators of inflammatory and degenerative diseases. *Annu. Rev. Neurosci.* **22**, 219-240 (1999).
 135. Gordon,S. Alternative activation of macrophages. *Nat. Rev. Immunol.* **3**, 23-35 (2003).
 136. Greenberg,C.S., Birckbichler,P.J., & Rice,R.H. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. *FASEB J.* **5**, 3071-3077 (1991).
 137. Greenwood,J. Characterization of a rat retinal endothelial cell culture and the expression of P-glycoprotein in brain and retinal endothelium in vitro. *J. Neuroimmunol.* **39**, 123-132 (1992).
 138. Greenwood,J. *et al.* SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics. *J. Neuroimmunol.* **71**, 51-63 (1996).
 139. Greenwood,J., Steinman,L., & Zamvil,S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. *Nat. Rev. Immunol.* **6**, 358-370 (2006).
 140. Griffin,M., Casadio,R., & Bergamini,C.M. Transglutaminases: nature's biological glues. *Biochem. J.* **368**, 377-396 (2002).
 141. Griffiths,M., Neal,J.W., & Gasque,P. Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. *Int. Rev. Neurobiol.* **82**, 29-55 (2007).
 142. Guan,J.L. Role of focal adhesion kinase in integrin signaling. *Int. J. Biochem. Cell Biol.* **29**, 1085-1096 (1997).
 143. Hall,A. Rho GTPases and the actin cytoskeleton. *Science* **279**, 509-514 (1998).
 144. Han,M.H. *et al.* Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. *Nature* **451**, 1076-1081 (2008).
 145. Hand,D., Perry,M.J., & Haynes,L.W. Cellular transglutaminases in neural development. *Int. J. Dev. Neurosci.* **11**, 709-720 (1993).
 146. Hanisch,U.K. & Kettenmann,H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. *Nat. Neurosci.* **10**, 1387-1394 (2007).
 147. Haroon,Z.A., Hettasch,J.M., Lai,T.S., Dewhirst,M.W., & Greenberg,C.S. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. *FASEB J.* **13**, 1787-1795 (1999).
 148. Harsan,L.A. *et al.* Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. *J. Neurosci.* **28**, 14189-14201 (2008).
 149. Hendriks,J.J., Teunissen,C.E., De Vries,H.E., & Dijkstra,C.D. Macrophages and neurodegeneration. *Brain Res. Brain Res. Rev.* **48**, 185-195 (2005).
 150. Hibbits,N., Pannu,R., John,W.T., & Armstrong,R.C. Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination. *ASN. Neuro.* **1**, (2009).
 151. Hickey,W.F. & Kimura,H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. *Science* **239**, 290-292 (1988).
 152. Hiremath,M.M., Chen,V.S., Suzuki,K., Ting,J.P., & Matsushima,G.K. MHC class II exacerbates demyelination in vivo independently of T cells. *J. Neuroimmunol.* **203**, 23-32 (2008).
 153. Hiremath,M.M. *et al.* Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. *J. Neuroimmunol.* **92**, 38-49 (1998).
 154. Hodrea,J. *et al.* Transglutaminase 2 is expressed and active on the surface of human monocyte-derived dendritic cells and macrophages. *Immunol. Lett.* (2010).
 155. Holley,J.E., Gveric,D., Newcombe,J., Cuzner,M.L., & Gutowski,N.J. Astrocyte characterization in the multiple sclerosis glial scar. *Neuropathol. Appl. Neurobiol.* **29**, 434-444 (2003).
 156. Honing,H. *et al.* RhoA activation promotes transendothelial migration of monocytes via ROCK. *J. Leukoc. Biol.* **75**, 523-528 (2004).
 157. Huang,D. *et al.* Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. *Immunol. Rev.* **177**, 52-67 (2000).
 158. Huitinga,I., van,R.N., de Groot,C.J., Uitdehaag,B.M., & Dijkstra,C.D. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. *J. Exp. Med.* **172**, 1025-1033 (1990).
 159. Hwang,K.C., Gray,C.D., Sivasubramanian,N., & Im,M.J. Interaction site of GTP binding Gh (transglutaminase II) with phospholipase C. *J. Biol. Chem.* **270**, 27058-27062 (1995).
 160. Hynes,R.O. Fibronectins. *Sci. Am.* **254**, 42-51 (1986).
 161. Iadecola,C. Neurovascular regulation in the normal brain and in Alzheimer's disease. *Nat. Rev. Neurosci.* **5**, 347-360 (2004).
 162. Iismaa,S.E. *et al.* The core domain of the tissue transglutaminase Gh hydrolyzes GTP and ATP. *Biochemistry* **36**, 11655-11664 (1997).

163. Iismaa, S.E., Mearns, B.M., Lorand, L., & Graham, R.M. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. *Physiol Rev.* **89**, 991-1023 (2009).
164. Iismaa, S.E., Wu, M.J., Nanda, N., Church, W.B., & Graham, R.M. GTP binding and signaling by Gh/transglutaminase II involves distinct residues in a unique GTP-binding pocket. *J. Biol. Chem.* **275**, 18259-18265 (2000).
165. Issazadeh, S. *et al.* Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-beta. *J. Neuroimmunol.* **69**, 103-115 (1996).
166. Iyoda, M. *et al.* IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta. *Am. J. Physiol Renal Physiol* **298**, F779-F787 (2010).
167. Jacobs, L.D. *et al.* Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Ann. Neurol.* **39**, 285-294 (1996).
168. Janiak, A., Zemskov, E.A., & Belkin, A.M. Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway. *Mol. Biol. Cell* **17**, 1606-1619 (2006).
169. Janzer, R.C. & Raff, M.C. Astrocytes induce blood-brain barrier properties in endothelial cells. *Nature* **325**, 253-257 (1987).
170. Jeffery, N.D. & Blakemore, W.F. Locomotor deficits induced by experimental spinal cord demyelination are abolished by spontaneous remyelination. *Brain* **120 (Pt 1)**, 27-37 (1997).
171. Jeitner, T.M., Fuchsbauer, H.L., Blass, J.P., & Cooper, A.J. A sensitive fluorometric assay for tissue transglutaminase. *Anal. Biochem.* **292**, 198-206 (2001).
172. Jeong, J.M., Murthy, S.N., Radek, J.T., & Lorand, L. The fibronectin-binding domain of transglutaminase. *J. Biol. Chem.* **270**, 5654-5658 (1995).
173. Jessen, K.R. & Mirsky, R. Glial cells in the enteric nervous system contain glial fibrillary acidic protein. *Nature* **286**, 736-737 (1980).
174. John, G.R. *et al.* Interleukin-1beta induces a reactive astroglial phenotype via deactivation of the Rho GTPase-Rock axis. *J. Neurosci.* **24**, 2837-2845 (2004).
175. Johnson, G.V. *et al.* Transglutaminase activity is increased in Alzheimer's disease brain. *Brain Res.* **751**, 323-329 (1997).
176. Johnson, K.P. *et al.* Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995. *Neurology* **57**, S16-S24 (2001).
177. Johnson, K.P. *et al.* Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. *Mult. Scler.* **6**, 255-266 (2000).
178. Johnson, T.S. *et al.* Tissue transglutaminase and the progression of human renal scarring. *J. Am. Soc. Nephrol.* **14**, 2052-2062 (2003).
179. Johnson, T.S. *et al.* Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. *J. Am. Soc. Nephrol.* **18**, 3078-3088 (2007).
180. Jones, R.A., Nicholas, B., Mian, S., Davies, P.J., & Griffin, M. Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. *J. Cell Sci.* **110 (Pt 19)**, 2461-2472 (1997).
181. Jovinge, S., Hultgardh-Nilsson, A., Regnstrom, J., & Nilsson, J. Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. *Arterioscler. Thromb. Vasc. Biol.* **17**, 490-497 (1997).
182. Junn, E., Ronchetti, R.D., Quezado, M.M., Kim, S.Y., & Mouradian, M.M. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. *Proc. Natl. Acad. Sci. U. S. A* **100**, 2047-2052 (2003).
183. Kaur, C., Hao, A.J., Wu, C.H., & Ling, E.A. Origin of microglia. *Microsc. Res. Tech.* **54**, 2-9 (2001).
184. Kelley, M.J. *et al.* Synergism of TNF and IL-1 in the induction of matrix metalloproteinase-3 in trabecular meshwork. *Invest Ophthalmol. Vis. Sci.* **48**, 2634-2643 (2007).
185. Kerr, J.F., Wyllie, A.H., & Currie, A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer* **26**, 239-257 (1972).
186. Kim, J.H. *et al.* Blood-neural barrier: intercellular communication at glio-vascular interface. *J. Biochem. Mol. Biol.* **39**, 339-345 (2006).
187. Kim, S.Y., Grant, P., Lee, J.H., Pant, H.C., & Steinert, P.M. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. *J. Biol. Chem.* **274**, 30715-30721 (1999).
188. Kim, S.Y., Jeong, E.J., & Steinert, P.M. IFN-gamma induces transglutaminase 2 expression in rat small intestinal cells. *J. Interferon Cytokine Res.* **22**, 677-682 (2002).
189. Kinney, H.C. Human myelination and perinatal white matter disorders. *J. Neurol. Sci.* **228**, 190-192 (2005).
190. Kipp, M., Clarner, T., Dang, J., Copray, S., & Beyer, C. The cuprizone animal model: new insights into an old story. *Acta Neuropathol.* **118**, 723-736 (2009).
191. Kirk, J., Plumb, J., Mirakhor, M., & McQuaid, S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. *J. Pathol.* **201**, 319-327 (2003).
192. Kleinschmidt-DeMasters, B.K. & Tyler, K.L. Progressive multifocal leukoencephalopathy complicating

- treatment with natalizumab and interferon beta-1a for multiple sclerosis. *N. Engl. J. Med.* **353**, 369-374 (2005).
193. Knight,C.R., Rees,R.C., & Griffin,M. Reduction in transglutaminase activity associated with tumour metastasis is due to the presence of an inactive form of the enzyme. *Biochem. Soc. Trans.* **18**, 681-682 (1990).
 194. Komoly,S. Experimental demyelination caused by primary oligodendrocyte dystrophy. Regional distribution of the lesions in the nervous system of mice [corrected]. *Ideggyogy. Sz* **58**, 40-43 (2005).
 195. Kornek,B. & Lassmann,H. Neuropathology of multiple sclerosis-new concepts. *Brain Res. Bull.* **61**, 321-326 (2003).
 196. Kotsakis,P. & Griffin,M. Tissue transglutaminase in tumour progression: friend or foe? *Amino. Acids* **33**, 373-384 (2007).
 197. Kreutzberg,G.W. Microglia: a sensor for pathological events in the CNS. *Trends Neurosci.* **19**, 312-318 (1996).
 198. Kubilus,J. & Baden,H.P. Isolation of two immunologically related transglutaminase substrates from cultured human keratinocytes. *In Vitro* **18**, 447-455 (1982).
 199. Kuhlmann,T. *et al.* Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. *Brain* **131**, 1749-1758 (2008).
 200. Kumar,S., Biancotti,J.C., Yamaguchi,M., & de,V.J. Combination of growth factors enhances remyelination in a cuprizone-induced demyelination mouse model. *Neurochem. Res.* **32**, 783-797 (2007).
 201. Kuncio,G.S. *et al.* TNF-alpha modulates expression of the tissue transglutaminase gene in liver cells. *Am. J. Physiol* **274**, G240-G245 (1998).
 202. Langer-Gould,A., Atlas,S.W., Green,A.J., Bollen,A.W., & Pelletier,D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. *N. Engl. J. Med.* **353**, 375-381 (2005).
 203. Lassmann,H. Basic mechanisms of brain inflammation. *J. Neural Transm. Suppl* **50**, 183-190 (1997).
 204. Lassmann,H. & Wisniewski,H.M. Chronic relapsing experimental allergic encephalomyelitis: morphological sequence of myelin degradation. *Brain Res.* **169**, 357-368 (1979).
 205. Lauffenburger,D.A. & Horwitz,A.F. Cell migration: a physically integrated molecular process. *Cell* **84**, 359-369 (1996).
 206. Ledeboer,A., Breve,J.J., Poole,S., Tilders,F.J., & van Dam,A.M. Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. *Glia* **30**, 134-142 (2000).
 207. Ledeboer,A. *et al.* Expression and regulation of interleukin-10 and interleukin-10 receptor in rat astroglial and microglial cells. *Eur. J. Neurosci.* **16**, 1175-1185 (2002).
 208. Lee,E.J., Kim,W.J., & Moon,S.K. Cordycepin suppresses TNF-alpha-induced invasion, migration and matrix metalloproteinase-9 expression in human bladder cancer cells. *Phytother. Res.* (2010).
 209. Lee,J. *et al.* Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. *J. Biol. Chem.* **279**, 53725-53735 (2004).
 210. Lee,S.J. *et al.* ICAM-1-induced expression of proinflammatory cytokines in astrocytes: involvement of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. *J. Immunol.* **165**, 4658-4666 (2000).
 211. Lesort,M., Chun,W., Tucholski,J., & Johnson,G.V. Does tissue transglutaminase play a role in Huntington's disease? *Neurochem. Int.* **40**, 37-52 (2002).
 212. Levine,J.M., Reynolds,R., & Fawcett,J.W. The oligodendrocyte precursor cell in health and disease. *Trends Neurosci.* **24**, 39-47 (2001).
 213. Ley,K., Laudanna,C., Cybulsky,M.I., & Nourshargh,S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat. Rev. Immunol.* **7**, 678-689 (2007).
 214. Liang,X., Draghi,N.A., & Resh,M.D. Signaling from integrins to Fyn to Rho family GTPases regulates morphologic differentiation of oligodendrocytes. *J. Neurosci.* **24**, 7140-7149 (2004).
 215. Liebetanz,D. & Merkler,D. Effects of commissural de- and remyelination on motor skill behavior in the cuprizone mouse model of multiple sclerosis. *Exp. Neurol.* **202**, 217-224 (2006).
 216. Lin,T.N., Te,J., Lee,M., Sun,G.Y., & Hsu,C.Y. Induction of basic fibroblast growth factor (bFGF) expression following focal cerebral ischemia. *Brain Res. Mol. Brain Res.* **49**, 255-265 (1997).
 217. Linda,H. *et al.* Progressive multifocal leukoencephalopathy after natalizumab monotherapy. *N. Engl. J. Med.* **361**, 1081-1087 (2009).
 218. Liu,B. & Hong,J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. *J. Pharmacol. Exp. Ther.* **304**, 1-7 (2003).
 219. Liu,S., Cerione,R.A., & Clardy,J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. *Proc. Natl. Acad. Sci. U. S. A* **99**, 2743-2747 (2002).
 220. Liu,Y.J., Kanzler,H., Soumelis,V., & Gilliet,M. Dendritic cell lineage, plasticity and cross-regulation. *Nat. Immunol.* **2**, 585-589 (2001).
 221. Lorand,L. & Conrad,S.M. Transglutaminases. *Mol. Cell Biochem.* **58**, 9-35 (1984).
 222. Lorand,L. & Graham,R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. *Nat. Rev. Mol. Cell Biol.* **4**, 140-156 (2003).
 223. Lorentzen,J.C. *et al.* Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. *J. Neuroimmunol.* **63**, 193-205 (1995).

224. Lublin, F.D., Maurer, P.H., Berry, R.G., & Tippett, D. Delayed, relapsing experimental allergic encephalomyelitis in mice. *J. Immunol.* **126**, 819-822 (1981).
225. Lublin, F.D. & Reingold, S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology* **46**, 907-911 (1996).
226. Mack, C.P., Somlyo, A.V., Hautmann, M., Somlyo, A.P., & Owens, G.K. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. *J. Biol. Chem.* **276**, 341-347 (2001).
227. Maggio, N., Sellitti, S., Capano, C.P., & Papa, M. Tissue-transglutaminase in rat and human brain: light and electron immunocytochemical analysis and in situ hybridization study. *Brain Res. Bull.* **56**, 173-182 (2001).
228. Mahoney, S.A., Wilkinson, M., Smith, S., & Haynes, L.W. Stabilization of neurites in cerebellar granule cells by transglutaminase activity: identification of midkine and galectin-3 as substrates. *Neuroscience* **101**, 141-155 (2000).
229. Maier, O. *et al.* Alteration of the extracellular matrix interferes with raft association of neurofascin in oligodendrocytes. Potential significance for multiple sclerosis? *Mol. Cell Neurosci.* **28**, 390-401 (2005).
230. Major, E.O. Reemergence of PML in natalizumab-treated patients--new cases, same concerns. *N. Engl. J. Med.* **361**, 1041-1043 (2009).
231. Man, S., Ubogu, E.E., & Ransohoff, R.M. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. *Brain Pathol.* **17**, 243-250 (2007).
232. Mangala, L.S., Fok, J.Y., Zorrilla-Calanca, I.R., Verma, A., & Mehta, K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. *Oncogene* **26**, 2459-2470 (2007).
233. Mann, A.P. *et al.* Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. *Cancer Res.* **66**, 8788-8795 (2006).
234. Mariani, P. *et al.* Ligand-induced conformational changes in tissue transglutaminase: Monte Carlo analysis of small-angle scattering data. *Biophys. J.* **78**, 3240-3251 (2000).
235. Mark, K.S. & Davis, T.P. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. *Am. J. Physiol Heart Circ. Physiol* **282**, H1485-H1494 (2002).
236. Martin-Saavedra, F.M. *et al.* Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis. *Mol. Immunol.* **44**, 3597-3607 (2007).
237. Martinez, J., Chalupowicz, D.G., Roush, R.K., Sheth, A., & Barsigian, C. Transglutaminase-mediated processing of fibronectin by endothelial cell monolayers. *Biochemistry* **33**, 2538-2545 (1994).
238. Mastroberardino, P.G. *et al.* "Tissue" transglutaminase contributes to the formation of disulphide bridges in proteins of mitochondrial respiratory complexes. *Biochim. Biophys. Acta* **1757**, 1357-1365 (2006).
239. Matic, I. *et al.* Characterization of transglutaminase type II role in dendritic cell differentiation and function. *J. Leukoc. Biol.* (2010).
240. Matsushima, G.K. & Morell, P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. *Brain Pathol.* **11**, 107-116 (2001).
241. Mattes, P.M. & Mattes, W.B. alpha-Naphthyl butyrate carboxylesterase activity in human and rat nasal tissue. *Toxicol. Appl. Pharmacol.* **114**, 71-76 (1992).
242. McCarthy, K.D. & de, V.J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. *J. Cell Biol.* **85**, 890-902 (1980).
243. McKerracher, L. *et al.* Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. *Neuron* **13**, 805-811 (1994).
244. Mehta, K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. *Int. J. Cancer* **58**, 400-406 (1994).
245. Mehta, K. Mammalian transglutaminases: a family portrait. *Prog. Exp. Tumor Res.* **38**, 1-18 (2005).
246. Melino, G. *et al.* Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. *Mol. Cell Biol.* **14**, 6584-6596 (1994).
247. Mian, S. *et al.* The importance of the GTP-binding protein tissue transglutaminase in the regulation of cell cycle progression. *FEBS Lett.* **370**, 27-31 (1995).
248. Millefiorini, E. *et al.* Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. *J. Neurol.* **244**, 153-159 (1997).
249. Miller, D.H. & Leary, S.M. Primary-progressive multiple sclerosis. *Lancet Neurol.* **6**, 903-912 (2007).
250. Milner, R. *et al.* Fibronectin- and vitronectin-induced microglial activation and matrix metalloproteinase-9 expression is mediated by integrins alpha5beta1 and alphavbeta5. *J. Immunol.* **178**, 8158-8167 (2007).
251. Minagar, A. *et al.* The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. *J. Neurol. Sci.* **202**, 13-23 (2002).
252. Mohan, K., Pinto, D., & Issekutz, T.B. Identification of tissue transglutaminase as a novel molecule involved in human CD8+ T cell transendothelial migration. *J. Immunol.* **171**, 3179-3186 (2003).
253. Monge, M., Kadiiski, D., Jacque, C.M., & Zalc, B. Oligodendroglial expression and deposition of four major myelin constituents in the myelin sheath during development. An in vivo study. *Dev. Neurosci.* **8**, 222-235 (1986).

References

254. Monsonego,A., Friedmann,I., Shani,Y., Eisenstein,M., & Schwartz,M. GTP-dependent conformational changes associated with the functional switch between Galpha and cross-linking activities in brain-derived tissue transglutaminase. *J. Mol. Biol.* **282**, 713-720 (1998).
255. Monsonego,A. *et al.* Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes. *J. Biol. Chem.* **272**, 3724-3732 (1997).
256. Morell,P. *et al.* Gene expression in brain during cuprizone-induced demyelination and remyelination. *Mol. Cell Neurosci.* **12**, 220-227 (1998).
257. Morgan,M.R., Humphries,M.J., & Bass,M.D. Synergistic control of cell adhesion by integrins and syndecans. *Nat. Rev. Mol. Cell Biol.* **8**, 957-969 (2007).
258. Mouchaers,K.T. *et al.* Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. *Am. J. Physiol Heart Circ. Physiol* **297**, H200-H207 (2009).
259. Murtaugh,M.P. *et al.* Induction of tissue transglutaminase in mouse peritoneal macrophages. *J. Biol. Chem.* **258**, 11074-11081 (1983).
260. Murthy,S.N. *et al.* Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity. *Proc. Natl. Acad. Sci. U. S. A* **99**, 2738-2742 (2002).
261. Muszbek,L., Yee,V.C., & Hevessy,Z. Blood coagulation factor XIII: structure and function. *Thromb. Res.* **94**, 271-305 (1999).
262. Nair,A., Frederick,T.J., & Miller,S.D. Astrocytes in multiple sclerosis: a product of their environment. *Cell Mol. Life Sci.* **65**, 2702-2720 (2008).
263. Nait-Oumesmar,B. *et al.* Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. *Proc. Natl. Acad. Sci. U. S. A* **104**, 4694-4699 (2007).
264. Nakaoka,H. Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. *Science* **264**, 1593-1596 (1994).
265. Nakayama,T., Momoki-Soga,T., & Inoue,N. Astrocyte-derived factors instruct differentiation of embryonic stem cells into neurons. *Neurosci. Res.* **46**, 241-249 (2003).
266. Nardacci,R. *et al.* Characterization of cell death pathways in human immunodeficiency virus-associated encephalitis. *Am. J. Pathol.* **167**, 695-704 (2005).
267. Navikas,V. & Link,H. Review: cytokines and the pathogenesis of multiple sclerosis. *J. Neurosci. Res.* **45**, 322-333 (1996).
268. Nedergaard,M. & Dirnagl,U. Role of glial cells in cerebral ischemia. *Glia* **50**, 281-286 (2005).
269. Neille,L.K., Goodin,D.S., Goodkin,D.E., & Hauser,S.L. Side effect profile of interferon beta-1b in MS: results of an open label trial. *Neurology* **46**, 552-554 (1996).
270. Neuhaus,O. *et al.* Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. *Proc. Natl. Acad. Sci. U. S. A* **97**, 7452-7457 (2000).
271. Nicholas,B., Smethurst,P., Verderio,E., Jones,R., & Griffin,M. Cross-linking of cellular proteins by tissue transglutaminase during necrotic cell death: a mechanism for maintaining tissue integrity. *Biochem. J.* **371**, 413-422 (2003).
272. Nimmerjahn,A. Astrocytes going live: advances and challenges. *J. Physiol* **587**, 1639-1647 (2009).
273. Nishiura,H., Shibuya,Y., & Yamamoto,T. S19 ribosomal protein cross-linked dimer causes monocyte-predominant infiltration by means of molecular mimicry to complement C5a. *Lab Invest* **78**, 1615-1623 (1998).
274. Nishiyama,A., Lin,X.H., Giese,N., Heldin,C.H., & Stallcup,W.B. Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. *J. Neurosci. Res.* **43**, 315-330 (1996).
275. Noble,M., Fok-Seang,J., Wolswijk,G., & Wren,D. Development and regeneration in the central nervous system. *Philos. Trans. R. Soc. Lond B Biol. Sci.* **327**, 127-143 (1990).
276. Norlund,M.A., Lee,J.M., Zainelli,G.M., & Muma,N.A. Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. *Brain Res.* **851**, 154-163 (1999).
277. Norton,W.T. Biochemistry of myelin. *Adv. Neurol.* **31**, 93-121 (1981).
278. Nunes,I., Gleizes,P.E., Metz,C.N., & Rifkin,D.B. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor beta. *J. Cell Biol.* **136**, 1151-1163 (1997).
279. Nurminskaya,M., Magee,C., Faverman,L., & Linsenmayer,T.F. Chondrocyte-derived transglutaminase promotes maturation of preosteoblasts in periosteal bone. *Dev. Biol.* **263**, 139-152 (2003).
280. Nurminskaya,M., Magee,C., Nurminsky,D., & Linsenmayer,T.F. Plasma transglutaminase in hypertrophic chondrocytes: expression and cell-specific intracellular activation produce cell death and externalization. *J. Cell Biol.* **142**, 1135-1144 (1998).
281. Oliverio,S., Amendola,A., Rodolfo,C., Spinedi,A., & Piacentini,M. Inhibition of "tissue" transglutaminase increases cell survival by preventing apoptosis. *J. Biol. Chem.* **274**, 34123-34128 (1999).
282. Palace,J. Clinical and laboratory characteristics of secondary progressive MS. *J. Neurol. Sci.* **206**, 131-134 (2003).
283. Park,E.S. *et al.* Phospholipase C-delta1 and oxytocin receptor signaling: evidence of its role as an effector. *Biochem. J.* **331** (Pt 1), 283-289 (1998).
284. Park,J.Y. *et al.* A novel array-based assay of in situ tissue transglutaminase activity in human umbilical vein endothelial cells. *Anal. Biochem.* **394**, 217-222 (2009).

285. Parsons,J.T., Martin,K.H., Slack,J.K., Taylor,J.M., & Weed,S.A. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. *Oncogene* **19**, 5606-5613 (2000).
286. Patrikios,P. *et al.* Remyelination is extensive in a subset of multiple sclerosis patients. *Brain* **129**, 3165-3172 (2006).
287. Paxinos,G. & Franklin,K.B.J. *The mouse brain in stereotaxic coordinates*(Elsevier Academic Press, Amsterdam ; Boston, 2004).
288. Pedersen,L.C. *et al.* Transglutaminase factor XIII uses proteinase-like catalytic triad to crosslink macromolecules. *Protein Sci.* **3**, 1131-1135 (1994).
289. Pekny,M. & Nilsson,M. Astrocyte activation and reactive gliosis. *Glia* **50**, 427-434 (2005).
290. Perry,M.J. & Haynes,L.W. Localization and activity of transglutaminase, a retinoid-inducible protein, in developing rat spinal cord. *Int. J. Dev. Neurosci.* **11**, 325-337 (1993).
291. Pfeiffer,S.E., Warrington,A.E., & Bansal,R. The oligodendrocyte and its many cellular processes. *Trends Cell Biol.* **3**, 191-197 (1993).
292. Piacentini,M. *et al.* Type 2 transglutaminase and cell death. *Prog. Exp. Tumor Res.* **38**, 58-74 (2005).
293. Piacentini,M. *et al.* Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress. *J. Neurochem.* **81**, 1061-1072 (2002).
294. Piacentini,M. *et al.* Differential growth of N- and S-type human neuroblastoma cells xenografted into scid mice. correlation with apoptosis. *J. Pathol.* **180**, 415-422 (1996).
295. Pietroni,V. *et al.* Inactive and highly active, proteolytically processed transglutaminase-5 in epithelial cells. *J. Invest Dermatol.* **128**, 2760-2766 (2008).
296. Pinkas,D.M., Strop,P., Brunger,A.T., & Khosla,C. Transglutaminase 2 undergoes a large conformational change upon activation. *PLoS. Biol.* **5**, e327 (2007).
297. Piredda,L. *et al.* Lack of 'tissue' transglutaminase protein cross-linking leads to leakage of macromolecules from dying cells: relationship to development of autoimmunity in MRLlpr/lpr mice. *Cell Death. Differ.* **4**, 463-472 (1997).
298. Pittier,R., Sauthier,F., Hubbell,J.A., & Hall,H. Neurite extension and in vitro myelination within three-dimensional modified fibrin matrices. *J. Neurobiol.* **63**, 1-14 (2005).
299. Polman,C.H. *et al.* A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N. Engl. J. Med.* **354**, 899-910 (2006).
300. Polman,C.H. & Uitdehaag,B.M. Drug treatment of multiple sclerosis. *West J. Med.* **173**, 398-402 (2000).
301. Prat,A., Biernacki,K., Wosik,K., & Antel,J.P. Glial cell influence on the human blood-brain barrier. *Glia* **36**, 145-155 (2001).
302. Prineas,J., Raine,C.S., & Wisniewski,H. An ultrastructural study of experimental demyelination and remyelination. 3. Chronic experimental allergic encephalomyelitis in the central nervous system. *Lab Invest* **21**, 472-483 (1969).
303. Prineas,J.W. *et al.* Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. *Lab Invest* **61**, 489-503 (1989).
304. Quan,G., Choi,J.Y., Lee,D.S., & Lee,S.C. TGF-beta1 up-regulates transglutaminase two and fibronectin in dermal fibroblasts: a possible mechanism for the stabilization of tissue inflammation. *Arch. Dermatol. Res.* **297**, 84-90 (2005).
305. Radek,J.T., Jeong,J.M., Murthy,S.N., Ingham,K.C., & Lorand,L. Affinity of human erythrocyte transglutaminase for a 42-kDa gelatin-binding fragment of human plasma fibronectin. *Proc. Natl. Acad. Sci. U. S. A* **90**, 3152-3156 (1993).
306. Raff,M.C. *et al.* Galactocerebroside is a specific cell-surface antigenic marker for oligodendrocytes in culture. *Nature* **274**, 813-816 (1978).
307. Raine,C.S., Snyder,D.H., Stone,S.H., & Bornstein,M.B. Suppression of acute and chronic experimental allergic encephalomyelitis in Strain 13 guinea pigs. A clinical and pathological study. *J. Neurol. Sci.* **31**, 355-367 (1977).
308. Ranscht,B., Clapshaw,P.A., Price,J., Noble,M., & Seifert,W. Development of oligodendrocytes and Schwann cells studied with a monoclonal antibody against galactocerebroside. *Proc. Natl. Acad. Sci. U. S. A* **79**, 2709-2713 (1982).
309. Reier,P.J. & Houle,J.D. The glial scar: its bearing on axonal elongation and transplantation approaches to CNS repair. *Adv. Neurol.* **47**, 87-138 (1988).
310. Ren,X.D. & Schwartz,M.A. Determination of GTP loading on Rho. *Methods Enzymol.* **325**, 264-272 (2000).
311. Rice,G.P., Hartung,H.P., & Calabresi,P.A. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. *Neurology* **64**, 1336-1342 (2005).
312. Ridet,J.L., Malhotra,S.K., Privat,A., & Gage,F.H. Reactive astrocytes: cellular and molecular cues to biological function. *Trends Neurosci.* **20**, 570-577 (1997).
313. Ridley,A.J. & Hall,A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. *Cell* **70**, 389-399 (1992).
314. Ritter,S.J. & Davies,P.J. Identification of a transforming growth factor-beta1/bone morphogenetic protein 4 (TGF-beta1/BMP4) response element within the mouse tissue transglutaminase gene promoter. *J. Biol. Chem.* **273**, 12798-12806 (1998).
315. Rivers,T.M., Sprunt,D.H., & Berry,G.P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. *J. Exp. Med.* **58**, 39-53 (1933).
316. Roberts,E.S. *et al.* Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS. *Am. J.*

- Pathol.* **162**, 2041-2057 (2003).
317. Robinson,N.J., Baker,P.N., Jones,C.J., & Aplin,J.D. A role for tissue transglutaminase in stabilization of membrane-cytoskeletal particles shed from the human placenta. *Biol. Reprod.* **77**, 648-657 (2007).
 318. Rodriguez,M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. *Brain Pathol.* **17**, 219-229 (2007).
 319. Rose,D.M., Fadok,V.A., Riches,D.W., Clay,K.L., & Henson,P.M. Autocrine/paracrine involvement of platelet-activating factor and transforming growth factor-beta in the induction of phosphatidylserine recognition by murine macrophages. *J. Immunol.* **155**, 5819-5825 (1995).
 320. Rothwell,N.J., Luheshi,G., & Toulmond,S. Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. *Pharmacol. Ther.* **69**, 85-95 (1996).
 321. Rudick,R.A. *et al.* In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. *Neurology* **50**, 1294-1300 (1998).
 322. Ruuls,S.R., Van Der Linden,S., Sontrop,K., Huitinga,I., & Dijkstra,C.D. Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors. *Clin. Exp. Immunol.* **103**, 467-474 (1996).
 323. Sakly,W., Thomas,V., Quash,G., & El,A.S. A role for tissue transglutaminase in alpha-gliadin peptide cytotoxicity. *Clin. Exp. Immunol.* **146**, 550-558 (2006).
 324. Sander,E.E., ten Klooster,J.P., van,D.S., van der Kammen,R.A., & Collard,J.G. Rac down-regulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. *J. Cell Biol.* **147**, 1009-1022 (1999).
 325. Sarafian,T.A. & Bredesen,D.E. Is apoptosis mediated by reactive oxygen species? *Free Radic. Res.* **21**, 1-8 (1994).
 326. Sarang,Z. *et al.* Some lessons from the tissue transglutaminase knockout mouse. *Amino. Acids* **36**, 625-631 (2009).
 327. Schenkel,A.R., Mamdouh,Z., & Muller,W.A. Locomotion of monocytes on endothelium is a critical step during extravasation. *Nat. Immunol.* **5**, 393-400 (2004).
 328. Schmitz,A.A., Govek,E.E., Bottner,B., & Van,A.L. Rho GTPases: signaling, migration, and invasion. *Exp. Cell Res.* **261**, 1-12 (2000).
 329. Schonrock,L.M., Kuhlmann,T., Adler,S., Bitsch,A., & Bruck,W. Identification of glial cell proliferation in early multiple sclerosis lesions. *Neuropathol. Appl. Neurobiol.* **24**, 320-330 (1998).
 330. Schreiber,T.H., Shinder,V., Cain,D.W., Alon,R., & Sackstein,R. Shear flow-dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm. *Blood* **109**, 1381-1386 (2007).
 331. Schroff,G., Neumann,C., & Sorg,C. Transglutaminase as a marker for subsets of murine macrophages. *Eur. J. Immunol.* **11**, 637-642 (1981).
 332. Schwaninger,M. *et al.* Bradykinin induces interleukin-6 expression in astrocytes through activation of nuclear factor-kappaB. *J. Neurochem.* **73**, 1461-1466 (1999).
 333. Schwartz,J.P. & Nishiyama,N. Neurotrophic factor gene expression in astrocytes during development and following injury. *Brain Res. Bull.* **35**, 403-407 (1994).
 334. Scott,L.J. & Figgitt,D.P. Mitoxantrone: a review of its use in multiple sclerosis. *CNS. Drugs* **18**, 379-396 (2004).
 335. Seiving,B., Ohlsson,K., Linder,C., & Stenberg,P. Transglutaminase differentiation during maturation of human blood monocytes to macrophages. *Eur. J. Haematol.* **46**, 263-271 (1991).
 336. Shi,F., Harman,J., Fujiwara,K., & Sottile,J. Collagen I matrix turnover is regulated by fibronectin polymerization. *Am. J. Physiol Cell Physiol* **298**, C1265-C1275 (2010).
 337. Shweke,N. *et al.* Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. *Am. J. Pathol.* **173**, 631-642 (2008).
 338. Sim,F.J. *et al.* Complementary patterns of gene expression by human oligodendrocyte progenitors and their environment predict determinants of progenitor maintenance and differentiation. *Ann. Neurol.* **59**, 763-779 (2006).
 339. Singh,U.S., Erickson,J.W., & Cerione,R.A. Identification and biochemical characterization of an 80 kilodalton GTP-binding/transglutaminase from rabbit liver nuclei. *Biochemistry* **34**, 15863-15871 (1995).
 340. Singh,U.S., Kunar,M.T., Kao,Y.L., & Baker,K.M. Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase-2. *EMBO J.* **20**, 2413-2423 (2001).
 341. Singh,U.S. *et al.* Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. *J. Biol. Chem.* **278**, 391-399 (2003).
 342. Siskova,Z., Baron,W., de Vries,H., & Hoekstra,D. Fibronectin impedes "myelin" sheet-directed flow in oligodendrocytes: a role for a beta 1 integrin-mediated PKC signaling pathway in vesicular trafficking. *Mol. Cell Neurosci.* **33**, 150-159 (2006).
 343. Siskova,Z. *et al.* Fibronectin attenuates process outgrowth in oligodendrocytes by mislocalizing MMP-9 activity. *Mol. Cell Neurosci.* **42**, 234-242 (2009).
 344. Skripuletz,T. *et al.* Cerebellar Cortical Demyelination in the Murine Cuprizone Model. *Brain Pathol.* (2009).
 345. Slaughter,T.F., Achyuthan,K.E., Lai,T.S., & Greenberg,C.S. A microtiter plate transglutaminase assay utilizing 5-(biotinamido)pentylamine as substrate. *Anal. Biochem.* **205**, 166-171 (1992).
 346. Small,J.V., Rottner,K., & Kaverina,I. Functional design in the actin cytoskeleton. *Curr. Opin. Cell Biol.* **11**, 54-60 (1999).
 347. Smilenov,L.B., Mikhailov,A., Pelham,R.J., Marcantonio,E.E., & Gundersen,G.G. Focal adhesion motility

- revealed in stationary fibroblasts. *Science* **286**, 1172-1174 (1999).
348. Sobel,R.A. The extracellular matrix in multiple sclerosis: an update. *Braz. J. Med. Biol. Res.* **34**, 603-609 (2001).
 349. Sobel,R.A. & Mitchell,M.E. Fibronectin in multiple sclerosis lesions. *Am. J. Pathol.* **135**, 161-168 (1989).
 350. Sofroniew,M.V. Molecular dissection of reactive astrogliosis and glial scar formation. *Trends Neurosci.* **32**, 638-647 (2009).
 351. Sofroniew,M.V. & Vinters,H.V. Astrocytes: biology and pathology. *Acta Neuropathol.* **119**, 7-35 (2010).
 352. Soliven,B. Calcium signaling in cells of oligodendroglial lineage. *Microsc. Res. Tech.* **52**, 672-679 (2001).
 353. Song,H. *et al.* Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells. *Stem Cells* **25**, 1431-1438 (2007).
 354. Sotgiu,S., Pugliatti,M., Rosati,G., & Sechi,G.P. Which syringomyelia is truly associated with multiple sclerosis? *J. Neurol. Sci.* **190**, 99-100 (2001).
 355. Steffen,B.J., Butcher,E.C., & Engelhardt,B. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. *Am. J. Pathol.* **145**, 189-201 (1994).
 356. Stenman,S. & Vaheri,A. Distribution of a major connective tissue protein, fibronectin, in normal human tissues. *J. Exp. Med.* **147**, 1054-1064 (1978).
 357. Stephens,P. *et al.* Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. *J. Cell Sci.* **117**, 3389-3403 (2004).
 358. Stidworthy,M.F., Genoud,S., Suter,U., Mantei,N., & Franklin,R.J. Quantifying the early stages of remyelination following cuprizone-induced demyelination. *Brain Pathol.* **13**, 329-339 (2003).
 359. Storch,M.K. *et al.* Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. *Brain Pathol.* **8**, 681-694 (1998).
 360. Striedinger,K. & Scemes,E. Interleukin-1beta affects calcium signaling and in vitro cell migration of astrocyte progenitors. *J. Neuroimmunol.* **196**, 116-123 (2008).
 361. Stuve,O., Chabot,S., Jung,S.S., Williams,G., & Yong,V.W. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. *J. Neuroimmunol.* **80**, 38-46 (1997).
 362. Summers,L., Kangwantsa,K., Nguyen,L., Kielty,C., & Pinteaux,E. Adhesion to the extracellular matrix is required for interleukin-1 beta actions leading to reactive phenotype in rat astrocytes. *Mol. Cell Neurosci.* **44**, 272-281 (2010).
 363. Szondy,Z. *et al.* Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. *Proc. Natl. Acad. Sci. U. S. A* **100**, 7812-7817 (2003).
 364. Takano,T. *et al.* Astrocyte-mediated control of cerebral blood flow. *Nat. Neurosci.* **9**, 260-267 (2006).
 365. Tambuyzer,B.R., Ponsaerts,P., & Nouwen,E.J. Microglia: gatekeepers of central nervous system immunology. *J. Leukoc. Biol.* **85**, 352-370 (2009).
 366. Telci,D., Collighan,R.J., Basaga,H., & Griffin,M. Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide. *J. Biol. Chem.* **284**, 29547-29558 (2009).
 367. Telci,D. *et al.* Fibronectin-tissue transglutaminase matrix rescues RGD-impaired cell adhesion through syndecan-4 and beta1 integrin co-signaling. *J. Biol. Chem.* **283**, 20937-20947 (2008).
 368. Thomas-Ecker,S. *et al.* Alteration in the gene expression pattern of primary monocytes after adhesion to endothelial cells. *Proc. Natl. Acad. Sci. U. S. A* **104**, 5539-5544 (2007).
 369. Thomazy,V. & Fesus,L. Differential expression of tissue transglutaminase in human cells. An immunohistochemical study. *Cell Tissue Res.* **255**, 215-224 (1989).
 370. Thompson,A.J. *et al.* Diagnostic criteria for primary progressive multiple sclerosis: a position paper. *Ann. Neurol.* **47**, 831-835 (2000).
 371. Tilling,T. *et al.* Expression and adhesive properties of basement membrane proteins in cerebral capillary endothelial cell cultures. *Cell Tissue Res.* **310**, 19-29 (2002).
 372. Tischner,D. & Reichardt,H.M. Glucocorticoids in the control of neuroinflammation. *Mol. Cell Endocrinol.* **275**, 62-70 (2007).
 373. Torkildsen,O., Brunborg,L.A., Myhr,K.M., & Bo,L. The cuprizone model for demyelination. *Acta Neurol. Scand. Suppl* **188**, 72-76 (2008).
 374. Torocsik,D., Bardos,H., Nagy,L., & Adany,R. Identification of factor XIII-A as a marker of alternative macrophage activation. *Cell Mol. Life Sci.* **62**, 2132-2139 (2005).
 375. Trapp,B.D. *et al.* Axonal transection in the lesions of multiple sclerosis. *N. Engl. J. Med.* **338**, 278-285 (1998).
 376. Tucholski,J. TG2 protects neuroblastoma cells against DNA-damage-induced stress, suppresses p53 activation. *Amino. Acids*(2010).
 377. Tucholski,J., Lesort,M., & Johnson,G.V. Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. *Neuroscience* **102**, 481-491 (2001).
 378. Tullman,M.J., Oshinsky,R.J., Lublin,F.D., & Cutter,G.R. Clinical characteristics of progressive relapsing multiple sclerosis. *Mult. Scler.* **10**, 451-454 (2004).
 379. Turner,P.M. & Lorand,L. Complexation of fibronectin with tissue transglutaminase. *Biochemistry* **28**, 628-635 (1989).
 380. Tuttolomondo,A., Di,R.D., di,S.R., Pinto,A., & Licata,G. Inflammatory cytokines in acute ischemic stroke. *Curr. Pharm. Des* **14**, 3574-3589 (2008).
 381. Upchurch,H.F., Conway,E., Patterson,M.K., Jr., & Maxwell,M.D. Localization of cellular transglutaminase on

- the extracellular matrix after wounding: characteristics of the matrix bound enzyme. *J. Cell Physiol* **149**, 375-382 (1991).
382. Van Dam,A.M. *et al.* Appearance of inducible nitric oxide synthase in the rat central nervous system after rabies virus infection and during experimental allergic encephalomyelitis but not after peripheral administration of endotoxin. *J. Neurosci. Res.* **40**, 251-260 (1995).
 383. Van der Laan,L.J., De Groot,C.J., Elices,M.J., & Dijkstra,C.D. Extracellular matrix proteins expressed by human adult astrocytes *in vivo* and *in vitro*: an astrocyte surface protein containing the CS1 domain contributes to binding of lymphoblasts. *J. Neurosci. Res.* **50**, 539-548 (1997).
 384. Van der Laan,L.J. *et al.* Macrophage phagocytosis of myelin *in vitro* determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. *J. Neuroimmunol.* **70**, 145-152 (1996).
 385. Van der Goes,A. *et al.* Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier *in vitro*. *FASEB J.* **15**, 1852-1854 (2001).
 386. Van Strien,M.E. *et al.* Appearance of Tissue Transglutaminase in Astrocytes in Multiple Sclerosis Lesions: A Role in Cell Adhesion and Migration? *Brain Pathol.* (2010).
 387. Van Strien,M.E. *et al.* Anti-inflammatory effect by lentiviral-mediated overexpression of IL-10 or IL-1 receptor antagonist in rat glial cells and macrophages. *Gene Ther.* **17**(5), 662-71 (2010)
 388. Van Assche,G. *et al.* Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. *N. Engl. J. Med.* **353**, 362-368 (2005).
 389. Van der Valk,P. & De Groot,C.J. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. *Neuropathol. Appl. Neurobiol.* **26**, 2-10 (2000).
 390. Van Horsen,J., Dijkstra,C.D., & de Vries,H.E. The extracellular matrix in multiple sclerosis pathology. *J. Neurochem.* **103**, 1293-1301 (2007).
 391. Verderio,E., Nicholas,B., Gross,S., & Griffin,M. Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of fibronectin, cell attachment, and cell death. *Exp. Cell Res.* **239**, 119-138 (1998).
 392. Verderio,E.A., Johnson,T., & Griffin,M. Tissue transglutaminase in normal and abnormal wound healing: review article. *Amino. Acids* **26**, 387-404 (2004).
 393. Verderio,E.A., Scarpellini,A., & Johnson,T.S. Novel interactions of TG2 with heparan sulfate proteoglycans: reflection on physiological implications. *Amino. Acids* **36**, 671-677 (2009).
 394. Verderio,E.A., Telci,D., Okoye,A., Melino,G., & Griffin,M. A novel RGD-independent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. *J. Biol. Chem.* **278**, 42604-42614 (2003).
 395. Vezza,R., Habib,A., & FitzGerald,G.A. Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. *J. Biol. Chem.* **274**, 12774-12779 (1999).
 396. Vos,C.M. *et al.* Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. *Neurobiol. Dis.* **20**, 953-960 (2005).
 397. Voskuhl,R.R. *et al.* Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. *J. Neurosci.* **29**, 11511-11522 (2009).
 398. Vosoughi,R. & Freedman,M.S. Therapy of MS. *Clin. Neurol. Neurosurg.* **112**, 365-385 (2010).
 399. Walz,W. Controversy surrounding the existence of discrete functional classes of astrocytes in adult gray matter. *Glia* **31**, 95-103 (2000).
 400. Wang,K.C. *et al.* Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. *Nature* **417**, 941-944 (2002).
 401. Wang,X. *et al.* Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. *J. Neurol. Sci.* **231**, 57-66 (2005).
 402. Warrington,A.E., Barbarese,E., & Pfeiffer,S.E. Differential myelinogenic capacity of specific developmental stages of the oligodendrocyte lineage upon transplantation into hypomyelinating hosts. *J. Neurosci. Res.* **34**, 1-13 (1993).
 403. Watson,C.M., Davison,A.N., Baker,D., O'Neill,J.K., & Turk,J.L. Suppression of demyelination by mitoxantrone. *Int. J. Immunopharmacol.* **13**, 923-930 (1991).
 404. Waubant,E. *et al.* Clinical characteristics of responders to interferon therapy for relapsing MS. *Neurology* **61**, 184-189 (2003).
 405. Webster,N.L. & Crowe,S.M. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. *J. Leukoc. Biol.* **80**, 1052-1066 (2006).
 406. Wehrle-Haller,B. & Imhof,B. The inner lives of focal adhesions. *Trends Cell Biol.* **12**, 382-389 (2002).
 407. Welch,A.M., Holda,J.H., & Swanborg,R.H. Regulation of experimental allergic encephalomyelitis. II. Appearance of suppressor cells during the remission phase of the disease. *J. Immunol.* **125**, 186-189 (1980).
 408. Willenborg,D.O. Experimental allergic encephalomyelitis in the Lewis rat: studies on the mechanism of recovery from disease and acquired resistance to reinduction. *J. Immunol.* **123**, 1145-1150 (1979).
 409. Williams,A., Piaton,G., & Lubetzki,C. Astrocytes—friends or foes in multiple sclerosis? *Glia* **55**, 1300-1312 (2007).
 410. Wilson,H.C., Scolding,N.J., & Raine,C.S. Co-expression of PDGF alpha receptor and NG2 by oligodendrocyte precursors in human CNS and multiple sclerosis lesions. *J. Neuroimmunol.* **176**, 162-173 (2006).
 411. Wilson,J.X. Antioxidant defense of the brain: a role for astrocytes. *Can. J. Physiol Pharmacol.* **75**, 1149-1163

- (1997).
412. Wolswijk,G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. *J. Neurosci.* **18**, 601-609 (1998).
 413. Worthylake,R.A., Lemoine,S., Watson,J.M., & Burridge,K. RhoA is required for monocyte tail retraction during transendothelial migration. *J. Cell Biol.* **154**, 147-160 (2001).
 414. Yamaguchi,H. & Wang,H.G. Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. *Mol. Cell Biol.* **26**, 569-579 (2006).
 415. Yang,J.T. & Hynes,R.O. Fibronectin receptor functions in embryonic cells deficient in alpha 5 beta 1 integrin can be replaced by alpha V integrins. *Mol. Biol. Cell* **7**, 1737-1748 (1996).
 416. Yednock,T.A. *et al.* Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. *Nature* **356**, 63-66 (1992).
 417. Yee,V.C. *et al.* Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. *Proc. Natl. Acad. Sci. U. S. A* **91**, 7296-7300 (1994).
 418. Yeruva,S., Ramadori,G., & Raddatz,D. NF-kappaB-dependent synergistic regulation of CXCL10 gene expression by IL-1beta and IFN-gamma in human intestinal epithelial cell lines. *Int. J. Colorectal Dis.* **23**, 305-317 (2008).
 419. Yong,V.W., Chabot,S., Stuve,O., & Williams,G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. *Neurology* **51**, 682-689 (1998).
 420. Younes-Rapozo,V. *et al.* A role for the MAPK/ERK pathway in oligodendroglial differentiation in vitro: stage specific effects on cell branching. *Int. J. Dev. Neurosci.* **27**, 757-768 (2009).
 421. Yuan,L. *et al.* Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. *Mol. Cancer Ther.* **4**, 1293-1302 (2005).
 422. Yuan,L. *et al.* Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. *Oncogene* **26**, 2563-2573 (2007).
 423. Zamvil,S.S. & Steinman,L. The T lymphocyte in experimental allergic encephalomyelitis. *Annu. Rev. Immunol.* **8**, 579-621 (1990).
 424. Zeller,N.K., Behar,T.N., Dubois-Dalcq,M.E., & Lazzarini,R.A. The timely expression of myelin basic protein gene in cultured rat brain oligodendrocytes is independent of continuous neuronal influences. *J. Neurosci.* **5**, 2955-2962 (1985).
 425. Zemskov,E.A., Janiak,A., Hang,J., Waghray,A., & Belkin,A.M. The role of tissue transglutaminase in cell-matrix interactions. *Front Biosci.* **11**, 1057-1076 (2006).
 426. Zemskov,E.A. *et al.* Regulation of platelet-derived growth factor receptor function by integrin-associated cell surface transglutaminase. *J. Biol. Chem.* **284**, 16693-16703 (2009).
 427. Zhang,A. *et al.* Mechanism of TNF-alpha-induced migration and hepatocyte growth factor production in human mesenchymal stem cells. *J. Cell Biochem.* (2010).
 428. Zipp,F. & Aktas,O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. *Trends Neurosci.* **29**, 518-527 (2006).